RDY
Dr. Reddy's Laboratories Ltd.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IN
$12.19
+0.00%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$12.18
From 52W high−20.74%
Volume1.89M
Market cap$10.15B
P/E (TTM)29.3x
P/S (TTM)2.9x
Div yield1.21%
Key dataSep 18, 2026
Open
$12.18
From 52W high
−20.74%
Volume
1.89M
Market cap
$10.15B
ValuationView details →
P/E (Fwd)
26.0x
EV/EBITDA
17.4x
P/E (TTM)
29.3x
RSI (14)
53.8
MomentumView details →
1D Return
+0.00%
YTD Return
−13.07%
SummaryUpdated Jun 1, 2026
Dr. Reddy's Laboratories Limited (NYSE:RDY) is an Indian multinational pharmaceutical company founded in 1984 and headquartered in Hyderabad, India. The company has evolved from a small startup into one of India's largest pharmaceutical companies, going public on the New York Stock Exchange in 2001. Dr. Reddy's operates as an integrated pharmaceutical company with a global presence, manufacturing and marketing generic drugs, active pharmaceutical ingredients, and developing proprietary products across multiple therapeutic areas including cardiovascular, gastrointestinal, oncology, and diabetes treatments.
Similar companies
Latest newsMore news →
Takeda's QDENGA, a live-attenuated tetravalent dengue vaccine, is set to become India's first approved dengue vaccine, with private-market availability expected in the first half of 2027.2d agoDr Reddy's Laboratories signed a distribution agreement with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.2d agoDr. Reddy's Laboratories launched NIVORZ, a nivolumab biosimilar of Bristol Myers Squibb's Opdivo, in India across 12 cancer indications, marking its entry into immuno-oncology.5d ago